# mPharma Health Nigeria

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mpharma-health-nigeria

- Industry: Healthcare IT
- Headquarters: Accra, Ghana
- Website: www.mpharma.com
- Total disclosed funding: $68M
- Latest round: Series D (Jan 5, 2022)
- Investors on record: 16

## About

Founded in 2014 and based in Accra, Ghana, mPharma Health Nigeria Limited operates an online solution that manages and monitors pharmaceutical drug availability and locations for health insurance and pharmaceutical companies. The company was founded by CEO Gregory Rockson, Daniel Shoukimas, and James Finucane. In 2012, it received its first funding from M12.

The company's product includes an online solution that manages and monitors the availability and location of pharmaceutical drugs. The company offers drug benefits services for health insurance companies and pharmaceutical companies that will help in delivering affordable medications for consumers. It also offers Mutti, a card solution that allows users to only pay a fraction of their medication and pay it over the course of their treatment through Mutti mobile money wallet and earn points for cash back. The company also provides QualityRX, a financing solution that in the development and improvement of pharmaceutical facilities and inventory.

## Funding rounds

- Series D, Jan 5, 2022, $30M — Lux Capital, Novastar Ventures, Social Capital, Unbound, To Ventures Food, Jam Fund, Northstar
- Series C, May 26, 2020, $17M — Novastar Ventures, CDC Group, Dompé Pharmaceuticals, Jam Fund, Alarko Ventures
- Series C, Jan 21, 2020 — Golden Palm Investments Corporation, Esas Holdings
- Series B, Jan 10, 2019 — Esas Holdings
- Series B, Dec 31, 2018, $9.7M — 4DX Ventures, Golden Palm Investments Corporation
- Series A, Nov 23, 2017, $6.6M — Social Capital, Breyer Capital, 4DX Ventures, Golden Palm Investments Corporation, Raba
- Seed, Dec 21, 2015, $5M — Social Capital, Singularity Investments
- Seed, Dec 1, 2015 — 4DX Ventures, Golden Palm Investments Corporation

## Investors

- 4DX Ventures (https://capitalatlas.ai/funds/4dx-ventures) — Seed, Series A, Series B
- Golden Palm Investments Corporation (https://capitalatlas.ai/funds/golden-palm-investments-corporation) — Seed, Series A, Series B, Series C
- Social Capital (https://capitalatlas.ai/funds/social-capital) — Seed, Series A, Series D
- Singularity Investments (https://capitalatlas.ai/funds/singularity-investments) — Seed
- Breyer Capital (https://capitalatlas.ai/funds/breyer-capital) — Series A
- Raba (https://capitalatlas.ai/funds/raba) — Series A
- Esas Holdings (https://capitalatlas.ai/funds/esas-holdings) — Series B, Series C
- Novastar Ventures (https://capitalatlas.ai/funds/novastar-ventures) — Series C, Series D
- CDC Group — Series C
- Dompé Pharmaceuticals — Series C
- Jam Fund (https://capitalatlas.ai/funds/jam-fund) — Series C, Series D
- Alarko Ventures (https://capitalatlas.ai/funds/alarko-ventures) — Series C
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series D
- Unbound (https://capitalatlas.ai/funds/unbound) — Series D
- To Ventures Food — Series D
- Northstar (https://capitalatlas.ai/funds/northstar) — Series D